Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252382 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
A Phase 2 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00252382 is a Phase 2 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT00252382, a Phase 2 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.
Interventions
- DRUG SNS-595 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2005-12-27 |
| Est. Completion | 2007-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252382
The ClinicalTrials.gov registry entry for NCT00252382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNS-595 Injection is the first listed.
NCT00252382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252382 about?
NCT00252382 is a clinical study titled "Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC". The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.
What is the current status of trial NCT00252382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2005-12-27. Estimated completion is 2007-11-29.
What interventions are being tested in trial NCT00252382?
The interventions under investigation include: SNS-595 Injection (DRUG).
Who is sponsoring clinical trial NCT00252382?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.